| Jan 15 | 2021 |
AVEO Oncology Announces Results from Phase 1b Portion of DEDUCTIVE Study of Tivozanib (FOTIVDA®) in Combination with IMFINZI® (durvalumab) in Previously Untreated Metastatic Hepatocellular Carcinoma |
| Jan 7 | 2021 |
AVEO Oncology Highlights Recent Progress and 2021 Outlook |
| Jan 6 | 2021 |
AVEO Oncology Announces Participation at Two Upcoming Investor Conferences |
| Jan 5 | 2021 |
AVEO Oncology Announces Webcast of Presentation at the 39th Annual J.P. Morgan Healthcare Conference |
